Jennifer Michele Manne-Goehler, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Chagas Disease | 14 | 2022 | 166 | 4.050 |
Why?
|
Diabetes Mellitus | 27 | 2023 | 5702 | 2.780 |
Why?
|
Developing Countries | 26 | 2024 | 2779 | 2.460 |
Why?
|
Rural Population | 22 | 2023 | 2181 | 2.170 |
Why?
|
South Africa | 19 | 2024 | 1743 | 1.720 |
Why?
|
HIV Infections | 24 | 2024 | 16764 | 1.600 |
Why?
|
Career Mobility | 2 | 2020 | 262 | 1.260 |
Why?
|
Trypanocidal Agents | 4 | 2020 | 38 | 1.250 |
Why?
|
Nitroimidazoles | 4 | 2020 | 106 | 1.170 |
Why?
|
Triatoma | 2 | 2018 | 13 | 1.090 |
Why?
|
Insect Control | 2 | 2018 | 28 | 1.080 |
Why?
|
Insect Vectors | 2 | 2018 | 133 | 1.010 |
Why?
|
Hypertension | 17 | 2024 | 8431 | 0.990 |
Why?
|
Income | 11 | 2023 | 1877 | 0.970 |
Why?
|
Faculty, Medical | 3 | 2020 | 1179 | 0.920 |
Why?
|
Antiretroviral Therapy, Highly Active | 4 | 2020 | 1896 | 0.860 |
Why?
|
Health Surveys | 9 | 2022 | 4022 | 0.800 |
Why?
|
Cross-Sectional Studies | 40 | 2024 | 24714 | 0.770 |
Why?
|
Poverty | 11 | 2022 | 2626 | 0.750 |
Why?
|
Body Mass Index | 6 | 2023 | 12655 | 0.750 |
Why?
|
Infectious Disease Medicine | 1 | 2020 | 49 | 0.730 |
Why?
|
Prevalence | 25 | 2022 | 15153 | 0.690 |
Why?
|
Insecticides | 2 | 2018 | 194 | 0.670 |
Why?
|
Trypanosoma cruzi | 5 | 2022 | 198 | 0.670 |
Why?
|
Nifurtimox | 2 | 2015 | 13 | 0.640 |
Why?
|
Diabetes Mellitus, Type 2 | 8 | 2023 | 11699 | 0.620 |
Why?
|
Delivery of Health Care | 5 | 2020 | 5272 | 0.600 |
Why?
|
Social Stigma | 2 | 2024 | 695 | 0.600 |
Why?
|
National Health Programs | 1 | 2020 | 445 | 0.580 |
Why?
|
Health Services Accessibility | 8 | 2020 | 5128 | 0.580 |
Why?
|
Blood Donors | 2 | 2016 | 357 | 0.560 |
Why?
|
Self Report | 6 | 2023 | 3524 | 0.540 |
Why?
|
Longitudinal Studies | 13 | 2024 | 13880 | 0.520 |
Why?
|
Anti-Retroviral Agents | 5 | 2020 | 1734 | 0.510 |
Why?
|
Comorbidity | 7 | 2020 | 10362 | 0.500 |
Why?
|
Sex Factors | 8 | 2021 | 10398 | 0.500 |
Why?
|
Self Concept | 1 | 2020 | 1024 | 0.490 |
Why?
|
Communicable Diseases | 2 | 2020 | 873 | 0.490 |
Why?
|
Cause of Death | 3 | 2022 | 3564 | 0.480 |
Why?
|
Drugs, Investigational | 2 | 2020 | 215 | 0.480 |
Why?
|
Rural Health Services | 1 | 2017 | 378 | 0.470 |
Why?
|
Cost of Illness | 3 | 2021 | 1849 | 0.460 |
Why?
|
Health Services Needs and Demand | 2 | 2019 | 1409 | 0.460 |
Why?
|
Obesity | 6 | 2023 | 12643 | 0.460 |
Why?
|
Parturition | 1 | 2017 | 431 | 0.450 |
Why?
|
Antiprotozoal Agents | 1 | 2013 | 86 | 0.450 |
Why?
|
Disabled Persons | 1 | 2023 | 1207 | 0.450 |
Why?
|
Adult | 57 | 2023 | 213394 | 0.450 |
Why?
|
Cardiovascular Diseases | 15 | 2024 | 15070 | 0.430 |
Why?
|
Rhodnius | 1 | 2012 | 4 | 0.430 |
Why?
|
Blood Pressure | 10 | 2022 | 8554 | 0.420 |
Why?
|
Medicine | 2 | 2020 | 930 | 0.420 |
Why?
|
Humans | 103 | 2024 | 739398 | 0.420 |
Why?
|
Educational Status | 1 | 2020 | 2514 | 0.410 |
Why?
|
Male | 60 | 2023 | 349022 | 0.400 |
Why?
|
Female | 62 | 2023 | 378853 | 0.390 |
Why?
|
Mexico | 6 | 2022 | 683 | 0.380 |
Why?
|
Circumcision, Male | 1 | 2011 | 139 | 0.370 |
Why?
|
Middle Aged | 50 | 2023 | 212863 | 0.370 |
Why?
|
Antihypertensive Agents | 4 | 2021 | 2039 | 0.370 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3021 | 0.370 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2749 | 0.360 |
Why?
|
Africa South of the Sahara | 5 | 2023 | 727 | 0.340 |
Why?
|
Achievement | 2 | 2020 | 291 | 0.330 |
Why?
|
Viral Load | 4 | 2022 | 3299 | 0.320 |
Why?
|
Blood Glucose | 7 | 2023 | 6237 | 0.320 |
Why?
|
Socioeconomic Factors | 10 | 2022 | 7726 | 0.310 |
Why?
|
Intensive Care Units | 2 | 2020 | 3672 | 0.310 |
Why?
|
India | 7 | 2022 | 2189 | 0.290 |
Why?
|
Financing, Government | 1 | 2010 | 470 | 0.290 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2022 | 1331 | 0.280 |
Why?
|
Mass Screening | 5 | 2022 | 5265 | 0.280 |
Why?
|
Hypercholesterolemia | 2 | 2023 | 1143 | 0.270 |
Why?
|
Aged | 33 | 2024 | 162698 | 0.260 |
Why?
|
Health Services Research | 2 | 2018 | 1832 | 0.260 |
Why?
|
AIDS Vaccines | 1 | 2011 | 924 | 0.260 |
Why?
|
Health Services | 1 | 2010 | 757 | 0.260 |
Why?
|
Longevity | 2 | 2023 | 1066 | 0.250 |
Why?
|
Primary Prevention | 1 | 2011 | 1165 | 0.240 |
Why?
|
Diabetes Complications | 3 | 2021 | 1356 | 0.240 |
Why?
|
Urban Population | 3 | 2022 | 2014 | 0.230 |
Why?
|
Developed Countries | 3 | 2023 | 433 | 0.230 |
Why?
|
Body Height | 2 | 2020 | 1577 | 0.220 |
Why?
|
Metabolic Diseases | 2 | 2022 | 658 | 0.220 |
Why?
|
Women | 2 | 2021 | 230 | 0.210 |
Why?
|
Tobacco, Smokeless | 1 | 2022 | 129 | 0.200 |
Why?
|
Zambia | 1 | 2022 | 260 | 0.200 |
Why?
|
Young Adult | 16 | 2022 | 56255 | 0.200 |
Why?
|
Leadership | 2 | 2021 | 1349 | 0.200 |
Why?
|
Risk Factors | 22 | 2023 | 71974 | 0.190 |
Why?
|
Housing | 2 | 2018 | 658 | 0.190 |
Why?
|
Uganda | 3 | 2021 | 1230 | 0.190 |
Why?
|
Anti-HIV Agents | 2 | 2017 | 4320 | 0.190 |
Why?
|
Cohort Studies | 8 | 2024 | 40389 | 0.190 |
Why?
|
United States | 12 | 2023 | 69573 | 0.180 |
Why?
|
Latin America | 2 | 2022 | 380 | 0.180 |
Why?
|
Emigration and Immigration | 1 | 2022 | 402 | 0.180 |
Why?
|
Program Evaluation | 2 | 2018 | 2484 | 0.170 |
Why?
|
Economic Development | 1 | 2019 | 69 | 0.170 |
Why?
|
Nicaragua | 1 | 2018 | 28 | 0.170 |
Why?
|
Life Expectancy | 2 | 2023 | 1208 | 0.160 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2023 | 3323 | 0.160 |
Why?
|
Lamivudine | 1 | 2019 | 342 | 0.160 |
Why?
|
Secondary Prevention | 2 | 2023 | 1516 | 0.160 |
Why?
|
Hypotension, Orthostatic | 1 | 2021 | 258 | 0.160 |
Why?
|
Population Density | 1 | 2018 | 194 | 0.160 |
Why?
|
Health Expenditures | 1 | 2010 | 2348 | 0.150 |
Why?
|
Adolescent | 15 | 2023 | 85405 | 0.150 |
Why?
|
Social Class | 3 | 2022 | 1974 | 0.150 |
Why?
|
Case Management | 1 | 2019 | 287 | 0.150 |
Why?
|
Population Surveillance | 2 | 2018 | 2629 | 0.150 |
Why?
|
Los Angeles | 1 | 2017 | 236 | 0.140 |
Why?
|
Interviews as Topic | 4 | 2019 | 2533 | 0.140 |
Why?
|
Posture | 1 | 2021 | 966 | 0.140 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2018 | 425 | 0.140 |
Why?
|
Sexual Partners | 1 | 2021 | 727 | 0.140 |
Why?
|
Endemic Diseases | 1 | 2016 | 181 | 0.140 |
Why?
|
Cultural Diversity | 1 | 2019 | 357 | 0.130 |
Why?
|
Focus Groups | 1 | 2020 | 1308 | 0.130 |
Why?
|
Texas | 1 | 2016 | 394 | 0.130 |
Why?
|
Florida | 1 | 2016 | 437 | 0.130 |
Why?
|
Fitness Centers | 1 | 2014 | 12 | 0.130 |
Why?
|
Risk-Taking | 1 | 2021 | 986 | 0.130 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2022 | 1377 | 0.130 |
Why?
|
Government Programs | 1 | 2017 | 277 | 0.120 |
Why?
|
Overweight | 2 | 2023 | 2355 | 0.120 |
Why?
|
Health Policy | 2 | 2017 | 2655 | 0.120 |
Why?
|
Referral and Consultation | 3 | 2021 | 3514 | 0.120 |
Why?
|
Aging | 4 | 2021 | 8613 | 0.120 |
Why?
|
Systems Analysis | 1 | 2015 | 170 | 0.120 |
Why?
|
New York | 1 | 2016 | 888 | 0.120 |
Why?
|
Health Care Costs | 2 | 2018 | 3226 | 0.120 |
Why?
|
Growth Disorders | 1 | 2019 | 644 | 0.120 |
Why?
|
Health | 1 | 2017 | 390 | 0.120 |
Why?
|
Fruit | 1 | 2019 | 1139 | 0.120 |
Why?
|
Vegetables | 1 | 2019 | 1178 | 0.120 |
Why?
|
Epidemiologic Research Design | 1 | 2017 | 368 | 0.110 |
Why?
|
Disease Vectors | 1 | 2013 | 60 | 0.110 |
Why?
|
Schools, Medical | 1 | 2020 | 878 | 0.110 |
Why?
|
Chronic Disease | 2 | 2020 | 9133 | 0.110 |
Why?
|
California | 1 | 2016 | 1400 | 0.110 |
Why?
|
HIV Antibodies | 1 | 2019 | 1309 | 0.110 |
Why?
|
Echocardiography, Stress | 1 | 2013 | 131 | 0.110 |
Why?
|
Pyrethrins | 1 | 2012 | 47 | 0.100 |
Why?
|
Weight Loss | 1 | 2023 | 2589 | 0.100 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3233 | 0.100 |
Why?
|
Cholesterol | 1 | 2021 | 2900 | 0.100 |
Why?
|
Parasitic Diseases | 1 | 2012 | 76 | 0.100 |
Why?
|
Logistic Models | 2 | 2020 | 13402 | 0.100 |
Why?
|
Guatemala | 1 | 2012 | 142 | 0.100 |
Why?
|
Alcohol Drinking | 2 | 2022 | 3945 | 0.100 |
Why?
|
Aspirin | 1 | 2023 | 3268 | 0.100 |
Why?
|
Diet | 2 | 2020 | 7876 | 0.100 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1054 | 0.100 |
Why?
|
Epidemics | 1 | 2017 | 520 | 0.100 |
Why?
|
Sexual Behavior | 1 | 2021 | 2040 | 0.100 |
Why?
|
Sex Characteristics | 2 | 2020 | 2583 | 0.100 |
Why?
|
Burkina Faso | 2 | 2021 | 88 | 0.090 |
Why?
|
Hyperglycemia | 1 | 2019 | 1357 | 0.090 |
Why?
|
Urban Health | 1 | 2013 | 547 | 0.090 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 514 | 0.090 |
Why?
|
Decision Support Techniques | 2 | 2011 | 1957 | 0.090 |
Why?
|
Fasting | 3 | 2021 | 1587 | 0.090 |
Why?
|
Depression | 2 | 2019 | 7689 | 0.090 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2560 | 0.090 |
Why?
|
Decision Support Systems, Clinical | 1 | 2018 | 1162 | 0.090 |
Why?
|
Glucose | 1 | 2021 | 4377 | 0.080 |
Why?
|
Pregnancy | 2 | 2023 | 29002 | 0.080 |
Why?
|
HIV Seronegativity | 2 | 2020 | 209 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 14740 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2019 | 2213 | 0.080 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 2012 | 0.080 |
Why?
|
Research | 1 | 2017 | 2001 | 0.080 |
Why?
|
Incidence | 4 | 2022 | 20913 | 0.080 |
Why?
|
Body Weights and Measures | 2 | 2019 | 209 | 0.080 |
Why?
|
Odds Ratio | 1 | 2020 | 9846 | 0.080 |
Why?
|
Hospitals | 1 | 2021 | 3916 | 0.070 |
Why?
|
Prospective Studies | 2 | 2023 | 53037 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3203 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3051 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2021 | 57650 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2018 | 2365 | 0.070 |
Why?
|
Environmental Monitoring | 1 | 2012 | 1408 | 0.070 |
Why?
|
Quality of Health Care | 1 | 2020 | 4365 | 0.060 |
Why?
|
Models, Theoretical | 2 | 2021 | 3609 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15511 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5401 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2491 | 0.060 |
Why?
|
Quality of Life | 3 | 2021 | 12640 | 0.060 |
Why?
|
International Cooperation | 1 | 2010 | 1420 | 0.060 |
Why?
|
Exercise | 2 | 2023 | 5591 | 0.060 |
Why?
|
Cognition | 1 | 2020 | 6686 | 0.060 |
Why?
|
C-Reactive Protein | 2 | 2017 | 3752 | 0.060 |
Why?
|
Age Distribution | 2 | 2019 | 2904 | 0.050 |
Why?
|
Health Care Surveys | 2 | 2020 | 2448 | 0.050 |
Why?
|
Neglected Diseases | 1 | 2022 | 64 | 0.050 |
Why?
|
Coronary Artery Disease | 2 | 2013 | 6416 | 0.050 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2023 | 213 | 0.050 |
Why?
|
Age Factors | 4 | 2021 | 18349 | 0.050 |
Why?
|
HIV-1 | 1 | 2019 | 6931 | 0.050 |
Why?
|
Coronary Angiography | 1 | 2013 | 4560 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 3 | 2013 | 1689 | 0.050 |
Why?
|
Review Literature as Topic | 1 | 2023 | 328 | 0.050 |
Why?
|
Indonesia | 1 | 2020 | 114 | 0.050 |
Why?
|
Sex Ratio | 1 | 2021 | 110 | 0.050 |
Why?
|
Saint Vincent and the Grenadines | 1 | 2020 | 3 | 0.050 |
Why?
|
Guyana | 1 | 2020 | 13 | 0.050 |
Why?
|
Serologic Tests | 1 | 2022 | 373 | 0.050 |
Why?
|
Bhutan | 1 | 2020 | 59 | 0.050 |
Why?
|
Antigens, CD19 | 1 | 2022 | 379 | 0.040 |
Why?
|
Georgia | 1 | 2020 | 184 | 0.040 |
Why?
|
Health Systems Plans | 1 | 2019 | 17 | 0.040 |
Why?
|
Electrocardiography | 1 | 2013 | 6426 | 0.040 |
Why?
|
Namibia | 1 | 2019 | 26 | 0.040 |
Why?
|
Clinical Competence | 1 | 2015 | 4671 | 0.040 |
Why?
|
Regression Analysis | 2 | 2019 | 6452 | 0.040 |
Why?
|
Nepal | 1 | 2020 | 289 | 0.040 |
Why?
|
Cell Count | 1 | 2022 | 1833 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 679 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2023 | 1339 | 0.040 |
Why?
|
Antifungal Agents | 1 | 2022 | 722 | 0.040 |
Why?
|
Markov Chains | 2 | 2013 | 970 | 0.040 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 441 | 0.040 |
Why?
|
Kenya | 1 | 2020 | 678 | 0.040 |
Why?
|
World Health Organization | 1 | 2023 | 1321 | 0.040 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 845 | 0.040 |
Why?
|
Blood | 1 | 2019 | 597 | 0.040 |
Why?
|
China | 1 | 2022 | 2225 | 0.030 |
Why?
|
Colombia | 1 | 2017 | 259 | 0.030 |
Why?
|
Heart Failure | 2 | 2011 | 10793 | 0.030 |
Why?
|
Geography | 1 | 2018 | 672 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3331 | 0.030 |
Why?
|
Research Personnel | 1 | 2021 | 571 | 0.030 |
Why?
|
Waist-Hip Ratio | 1 | 2017 | 517 | 0.030 |
Why?
|
Risk Assessment | 3 | 2021 | 23294 | 0.030 |
Why?
|
Animals | 3 | 2018 | 168368 | 0.030 |
Why?
|
HIV Seropositivity | 1 | 2020 | 966 | 0.030 |
Why?
|
Editorial Policies | 1 | 2019 | 446 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1749 | 0.030 |
Why?
|
Cost-Benefit Analysis | 3 | 2013 | 5462 | 0.030 |
Why?
|
Specialization | 1 | 2019 | 776 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2021 | 1407 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2296 | 0.030 |
Why?
|
Gender Identity | 1 | 2019 | 674 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1239 | 0.030 |
Why?
|
Smoking | 2 | 2021 | 8960 | 0.030 |
Why?
|
Forecasting | 1 | 2022 | 2952 | 0.030 |
Why?
|
Observer Variation | 1 | 2019 | 2589 | 0.030 |
Why?
|
Drug Costs | 1 | 2020 | 1115 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1584 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1675 | 0.030 |
Why?
|
Minority Groups | 1 | 2019 | 1197 | 0.030 |
Why?
|
Mothers | 1 | 2022 | 2143 | 0.020 |
Why?
|
Disclosure | 1 | 2017 | 735 | 0.020 |
Why?
|
Mortality | 1 | 2022 | 2851 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15036 | 0.020 |
Why?
|
Disease Progression | 3 | 2013 | 13237 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2021 | 2711 | 0.020 |
Why?
|
Peru | 1 | 2013 | 879 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2013 | 20055 | 0.020 |
Why?
|
Thailand | 1 | 2010 | 296 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2022 | 76631 | 0.020 |
Why?
|
Community Health Services | 1 | 2014 | 652 | 0.020 |
Why?
|
Computer Simulation | 1 | 2022 | 6237 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2018 | 5058 | 0.020 |
Why?
|
Hospitalization | 1 | 2008 | 10208 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9684 | 0.020 |
Why?
|
Population Dynamics | 1 | 2010 | 300 | 0.020 |
Why?
|
Condoms | 1 | 2010 | 321 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1175 | 0.020 |
Why?
|
Insulin | 1 | 2023 | 6569 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8039 | 0.020 |
Why?
|
Lipids | 1 | 2017 | 3307 | 0.020 |
Why?
|
Substance Abuse, Intravenous | 1 | 2010 | 523 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 7897 | 0.020 |
Why?
|
Patient Compliance | 1 | 2014 | 2679 | 0.010 |
Why?
|
Primary Health Care | 1 | 2020 | 4537 | 0.010 |
Why?
|
Health Status | 1 | 2017 | 4013 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3138 | 0.010 |
Why?
|
Health Behavior | 1 | 2014 | 2624 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8274 | 0.010 |
Why?
|
Homosexuality, Male | 1 | 2010 | 1239 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 28901 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2010 | 2334 | 0.010 |
Why?
|
Infant | 1 | 2022 | 34923 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7626 | 0.010 |
Why?
|
Algorithms | 1 | 2018 | 13872 | 0.010 |
Why?
|
Models, Statistical | 1 | 2011 | 5113 | 0.010 |
Why?
|
Child | 1 | 2022 | 77033 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2021 | 20676 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2019 | 62693 | 0.010 |
Why?
|